![]() |
|
|
Vol. 293, Issue 2, 480-486, May 2000
Departments of Pharmacology (K.R.H, I.J.R.) and Neurobiology
(B.A.M.), University of Pittsburgh School of Medicine, Pittsburgh,
Pennsylvania; and Department of Neurology (D.S.H.), The Ohio State
University College of Medicine, Columbus, Ohio
In central neurons, glutamate receptor activation causes massive
calcium influx and induces a mitochondrial depolarization, which is
partially blocked by cyclosporin A, suggesting a possible activation of
the mitochondrial permeability transition pore (PTP) as a mechanism. It
has been recently reported that tamoxifen (an antiestrogen
chemotherapeutic agent) blocks the PTP in isolated liver mitochondria,
similar to cyclosporin A. In this study, we tested whether
tamoxifen inhibits the mitochondrial depolarization induced by
glutamate receptor activation in intact cultured neurons loaded with
the fluorescent dye
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide. This dye reports disruptions in mitochondrial membrane potential, which can be caused by PTP activation. We found that glutamate (100 µM for 10 min) causes a robust mitochondrial
depolarization that is partially inhibited by tamoxifen. The maximum
inhibitory concentration of tamoxifen was 0.3 µM, with concentrations
higher and lower than 0.3 µM being less effective. However, although tamoxifen (0.3 µM) blocked glutamate-induced mitochondrial
depolarization, it did not inhibit glutamate-induced neuronal death, in
contrast to the PTP inhibitor cyclosporin A. A relatively high
concentration of tamoxifen (100 µM) caused mitochondrial
depolarization itself and was neurotoxic. These data suggest that
tamoxifen may be an inhibitor of the PTP in intact neurons. However,
the lack of specificity of most PTP inhibitors, and the difficulty in
measuring PTP in intact cells, preclude definite conclusions about the
role of PTP in excitotoxic injury.
This article has been cited by other articles:
![]() |
I. G. Stavrovskaya, M. V. Narayanan, W. Zhang, B. F. Krasnikov, J. Heemskerk, S. S. Young, J. P. Blass, A. M. Brown, M. F. Beal, R. M. Friedlander, et al. Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology J. Exp. Med., July 19, 2004; 200(2): 211 - 222. [Abstract] [Full Text] [PDF] |
||||